Barry Austin
Internal Medicine · Mc Murray, PANPI 1700856382
Payments from drug & device makers
Across 208 payments — averaging $547.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kowa Research Institute, Inc.$102K
- Teva Pharmaceuticals USA, Inc.$5K
- Boehringer Ingelheim$5K
- Novo Nordisk$369
- AbbVie$343
- GSK$329
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$161%
- Food & beverage$2,47299%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kowa Research Institute, Inc. | 33 | $101,541 |
| Teva Pharmaceuticals USA, Inc. | 6 | $5,388 |
| Boehringer Ingelheim | 9 | $4,502 |
| Novo Nordisk | 21 | $369 |
| AbbVie(2 entities) | 20 | $343 |
| GSK | 25 | $329 |
| AstraZeneca | 16 | $287 |
| Johnson & Johnson | 14 | $184 |
| Pfizer | 16 | $180 |
| Astellas Pharma US Inc | 8 | $138 |
| Lilly USA, LLC | 9 | $133 |
| Amgen | 7 | $115 |
| Sanofi-aventis U.S. LLC | 5 | $66 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $59 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $48 |
| Amarin Pharma, Inc. | 2 | $43 |
| Novartis | 2 | $28 |
| Arbor Pharmaceuticals, Inc. | 2 | $27 |
| Merck | 2 | $26 |
| E.r. Squibb & Sons, L.L.C. | 2 | $23 |
| Acorda Therapeutics, Inc | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
How this compares
$113,859 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 18 | $4,013 |
| Quetiapine Fumarate | 12 | $474 |
| Atorvastatin Calcium | 24 | $353 |
| Levothyroxine Sodium | 32 | $333 |
| Simvastatin | 15 | $207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $138 | $4,01318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.
Other internal medicine in Mc Murray
- Jonathan EpsteinPhiladelphia$13.1M
- Siddharth ShethPittsburgh$11M
- Nathan PatelTannersville$9.5M
- Pitamber DevgonPhiladelphia$7.5M
- Christopher StillDanville$7.1M
- Liza VillaruzPittsburgh$6.6M
- Paul HartleyUniontown$4.9M
- Victor KoladeSayre$4.7M
- Michael OliverBeaver$4.7M
- Raman PurighallaPittsburgh$3.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.